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The heptapeptide angiotensin (Ang)–(1-7) is part of the beneficial arm of the renin-
angiotensin system. Ang-(1-7) has cardiovascular protective effects, stimulates 
regeneration, and opposes the often detrimental effects of Ang II. We recently identified 
the G protein-coupled receptors Mas and MrgD as receptors for the heptapeptide. Ala1-
Ang-(1-7) (Alamandine), a decarboxylated form of Ang-(1-7), has similar vasorelaxant 
effects, but has been described to only stimulate MrgD. Therefore, this study aimed to 
characterise the consequences of the lack of the carboxyl group in amino acid 1 on 
intracellular signalling and to identify the receptor fingerprint for Ala1-Ang-(1-7).  
In primary endothelial and mesangial cells, Ala1-Ang-(1-7) elevated cAMP 
concentration. Dose response curves generated with Ang-(1-7) and Ala1-Ang-(1-7) 
significantly differed from each other, with a much lower EC50 and a bell-shape curve 
for Ala1-Ang-(1-7). We provided pharmacological proof that both, Mas and MrgD, are 
functional receptors for Ala1-Ang-(1-7). Consequently, in primary mesangial cells with 
genetic deficiency in both receptors the heptapeptide failed to increase cAMP 
concentration. As we previously described for Ang-(1-7), the Ala1-Ang-(1-7)-mediated 
cAMP increase in Mas/MrgD-transfected HEK293 cells and primary cells were blocked 
by the AT2 receptor blocker, PD123319. The very distinct dose-response curves for both 
heptapeptides could be explained by in silico modelling, electrostatic potential calculations, 
and an involvement of Galpha i for higher concentrations of Ala
1-Ang-(1-7).  
Our results identify Ala1-Ang-(1-7) as a peptide with specific pharmacodynamic properties 
and build the basis for the design of more potent and efficient Ang-(1-7) analogues for 
therapeutic interventions in a rapidly growing number of diseases. 
Keywords : Ala1-Angiotensin-(1-7), dose-response curve, G-proteins, Mas receptor, MrgD 




The renin-angiotensin system consists of an increasing number of angiotensin (Ang) 
peptides which play an important role in the regulation of arterial blood pressure, 
electrolyte homeostasis, and water and sodium intake (Crowley et al., 2012), as well as in 
processes like tissue regeneration (Takeda et al., 2004, Wang et al., 2010). The renin-
angiotensin system is a complex cascade in which precursor peptides are processed by 
specific enzymes to their active forms. In the past few years especially, Ang-(1-7) has 
become a peptide of interest, because of its beneficial actions in cardiovascular and renal 
diseases, counter-regulating the adverse effects of AngII (Mercure et al., 2008). Ang-(1-7) is 
mainly produced from AngII by Ang converting enzyme 2 (ACE2) (Vickers et al., 2002). 
In previous work, we identified the G protein-coupled receptor Mas to be associated with 
Ang-(1-7)-induced signalling which could be blocked by D-Ala7-Ang-(1-7), also named 
A779, a specific Ang-(1-7) antagonist (Santos et al., 2003). Very recently, we also 
discovered a second receptor for the heptapeptide, the Mas-related G protein-coupled 
receptor MrgD (Tetzner et al., 2016). In that study, we also showed that the primary 
intracellular pathway activated by Ang-(1-7) interactions with either Mas or MrgD 
involves adenylyl cyclase, cAMP and phosphokinase A (Tetzner et al., 2016).  
A decade ago, Jankowski et al. identified a modified analogue of AngII in human plasma 
(Jankowski et al., 2007). This Ala1-AngII, the authors named AngA, can be generated by 
the decarboxylation of the amino acid aspartate on position one to alanine. AngA interacts 
with the AT1 receptor (Yang et al., 2010) and its physiological effects can be blocked by 
the AT1 receptor blocker candesartan (Yang et al., 2011). Based on such findings, an 
international team hypothesized the existence of Ala1-Ang-(1-7) as a product of Ala1-
AngII through conversion by ACE2 (Lautner et al., 2013). Indeed, Ala1-Ang-(1-7) has 
been identified and named alamandine. As Kupchan et al. used  similar terminology, 
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Allamandin, for a completely different molecule, we will use the original term, Ala1-Ang-
(1-7), describing the amino acid change in Ang-(1-7), to prevent confusion (Kupchan et al., 
1974). Lautner et al. characterized Ala1-Ang-(1-7) as the target peptide for the MrgD 
receptor but not for the Mas receptor (Lautner et al., 2013). However, as we could show 
that Ang-(1-7) can stimulate both Mas and MrgD, we aimed to test whether Ala1-Ang-(1-
7) targets the same receptors as Ang-(1-7), or shows a distinct receptor fingerprint. In 
particular, we focused on the characterisation of the ligand/receptor pharmacology, by 
determining efficiency and potency using receptor-transfected HEK293 cells, human 
endothelial cells, receptor-deficient primary mesangial cells, and a variety of receptor 
blockers and enzyme inhibitors.  
 
 
2. Materials and Methods 
2. 1  Materials 
Angiotensin (Ang)-(1-7), Ala1-Ang-(1-7), D-Ala7-Ang-(1-7), and D-Pro7-Ang-(1-7) were 
synthetized from Biosyntan (Berlin, Germany). HEK293, Forskolin, RPMI-1640, HEPES 
solution, Sodium pyruvate, Trtiton X-100 and trypsin/EDTA were purchased from Sigma 
Aldrich (St. Louise, Missouri, USA). DMEM, Fetal Bovine Serum (FBS) and L-glutamine 
were purchased from GIBCO (Life Technologies, Carlsbad, California, USA). PD123319 
was from Parke-Davis Pharmaceutical Research (Detroit, Michigan, USA). Pertussis toxin 
(PTX) was from EMD Millipore (Billerica, MA, USA). Polyfect transfection reagent from 
Qiagen (Venlo, Limburg, Netherlands), and Pierce BCA Protein Assay Kit from Thermo 
Fisher Scientific (Waltham, Massachusetts, USA). NF 023 was purchased from Tocris 
5 
 
Bioscience (Bristol, United Kingdom). Direct cAMP ELISA kit was from Enzo Life 
Sciences Ltd. (Exeter, United Kingdom). HUVEC were purchased from LONZA (Basel, 
Switzerland). 
 
2. 2  Animals 
Mice deficient in Mas, MrgD (Walther et al., 1998, Zylka et al., 2005) and both Mas and 
MrgD (double knockout) (Tetzner et al., 2016) have been bred and housed in the animal 
facilities at UCC, Cork, Ireland. Animal studies are reported in compliance with the ARRIVE 
guidelines (Kilkenny et al., 2010, McGrath et al., 2015). Experiments performed conformed 
with the guidelines from Directive 2010/63/EU of the European Parliament on the protection 
of animals used for scientific purposes. Experiments involving animals have been approved 
by the local Animal Experimentation Ethics Committee (AEEC) in UCC, and also by the 
Health Products Regulatory Authority (HPRA).  
 
2. 3  Cell culture conditions, transfection and stimulation 
Human embryonic kidney (HEK-293) cells were cultured in DMEM medium supplemented 
with FBS (10%), HEPES buffer (1%), sodium pyruvate (1%), and L-glutamine (1%) and 
maintained under standard conditions (5% CO2, 95 % humidity and 37º C). Cells were 
cultured in 100mm cell culture dishes and seeded in 48-well plates at a density of 75,000 
cells per well. The next day, HEK-293 cells were transfected using a transient transfection 
procedure following the manufacturer’s instructions. Briefly, 150ng of control plasmid 
pcDNA3.1 or a combination of 50ng of pcDNA3.1 and 100ng of expression vectors 
containing the cDNA for Mas or MrgD were mixed with serum-free medium and PolyFect 
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transfection reagent. After 10min incubation at room temperature, which allowed the 
complex formation, complete medium was added and the total volume was transferred into 
appropriate wells of the 48-well plate. The cells were incubated for 16-20h. The next day, the 
medium was replaced by serum-free medium 1h before stimulation. After stimulation with 
A779, D-Pro, PD123319, Forskolin (all 10-6M), NF 023 (5x10-6M) or PTX (50ng/ml) for 
15min, the solvent, Ala1-Ang-(1-7) or Ang-(1-7) (all in the mentioned concentrations) were 
added for 15min. Then, the cells were lysed by adding 180µl/well of 0.1M hydrochloric acid 
with 0.1% Triton X-100, and the lysates were stored at −80°C until cAMP measurement. The 
protein concentration was determined using Pierce BCA Protein Assay Kit according to the 
manufacturer’s protocol (Thermo Fisher Scientific, Waltham, Massachusetts, USA).  
For fluoresence imaging, HEK293 cells were grown to 80-90% confluence and 
transfected with Mas-mCherry or MrgD-GFP constructs as described above.  
 
2. 4  Isolation and culture of primary cells and their stimulation 
Kidney mesangial cells (MC) were isolated from 10-12-week old mice deficient in Mas and 
MrgD, and from their age- and gender-matched C57/BL6 control, according to the protocol 
previously described (Zhu et al., 2013). MC were cultured in 75cm2 tissue culture flasks and 
seeded at passage 2 for stimulation in 24-well plates at a density of 100,000 cells per well.  
Primary human umbilical vein endothelial cells (HUVEC) were purchased from LONZA 
(Basel, Switzerland). HUVEC were cultured in 100mm cell culture dishes and were seeded at 
75,000 per well in 24-well plates at passage 5-7, for stimulation. Stimulation with Ala1-Ang-






2. 5  Measurement of cAMP in cell lysates  
cAMP concentration in cell lysates was determined using Direct cAMP ELISA kit (Enzo Life 
Sciences Ltd., Exeter, United Kingdom). Briefly, wells of 96-well plate (Goat Anti-Rabbit 
IgG pre-coated) were neutralized with 50µl of Neutralizing Reagent. Next, 100μl of 
acetylated cAMP standard or cell lysate was added, followed by 50µl of blue cAMP-Alkaline 
Phosphatase Conjugate and 50µl of yellow EIA Rabbit Anti-cAMP antibody. The plate was 
then incubated on a shaker (~ 400rpm) at room temperature for 2h. Next, the wells were 
aspirated and rinsed three times with Wash Buffer (1:10, Tris buffered saline containing 
detergents and sodium azide in deionized water). After the final wash, the plate was tapped 
against clean paper towel to remove any remaining Wash Buffer. To each well, 200µl p-
Nitrophenyl Phosphate Substrate Solution was added, and the plate was incubated for 1h at 
room temperature. The enzymatic reaction was stopped by adding 50µl of Stop Solution, and 
the absorbance at 405 nm was measured immediately. The cAMP concentration was 
determined from non-linear standard curve using GraphPad Prism 6.0 software.  
 
2. 6  mRNA isolation and real-time PCR 
Total cellular RNA was isolated using the NucleoSpin RNA isolation kit (MACHEREY-
NAGEL, Düren, Germany) according to the manufacturer’s protocol. After isolation, 2,000ng 
total RNA was transcribed into cDNA using the RevertAid H Minus First Strand cDNA 
Synthesis kit (MBI Fermentas, Hanover, MD, USA) and oligo(dT)18 primer according to the 
manufacturer’s guidelines. After synthesis, RNAse free water was added to the single cDNA 
to a final volume of 100µl. Quantification of mRNA levels was performed by real-time 
quantitative PCR (RT-PCR) on the StepOne™ Real-Time PCR System (Thermo Fisher 
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Scientific, Waltham, Massachusetts, USA) employing the Platinum SYBR Green qPCR 
SuperMix-UDG (Invitrogen) and gene specific primers (Mas forward: 
CCATCCTCAGCTTCTTGGTCTT, Mas reverse: TGGGAACCTGCATAACATCTCC, 
MrgD forward: AACAAACACCAGTGCTTCAAGG, MrgD reverse: 
CGTTTCACATCCACCCAGTAGA). The amplifications were performed in a final volume 
of 20µl using the following PCR cycle: 95°C for 15min followed by 40 cycles with 
denaturation at 95°C for 30s, annealing at 58°C for 30s and elongation at 72°C for 30s. PCR 
products were finally subjected to a melting curve analysis. The mRNA levels were 
quantified with the StepOne™ analysis software in comparative quantitation mode and 
normalized to beta-Actin expression levels. All quantitative RT-PCRs were performed at 
least three times in duplicate using RNA from independent experiments. 
 
2. 7  In silico modelling 
The 3-dimensional structure of Ang-(1–7) was prepared by minimizing their nuclear 
magnetic resonance experimental structures (PDB:2JP8) with Schrödinger Macromodel 
(MacroModel, version 9.7, Schrödinger, LLC, New York, NY), using AMBER94 force field 
and water solvent. It was further docked (keeping the backbone rigid) with Autodock 4.2.3 
(Huey et al., 2007) into a modeled structure of the Mas receptor (Horn et al., 2003), in which 
the F112 side chain conformation was further modified to create a larger binding site and to 
expose specific binding residues (Perodin et al., 2002, Prokop et al., 2013). The complex was 
minimized as before. Surface areas and electrostatic potentials were computed with 
Schrödinger Maestro (Maestro, version 11.3.016, Release 2017-3, Platform Linux-x86_64, 






2. 8  Statistical Analyses 
To ensure reproducibility of the results and to minimize bias, HEK293 cells, MC, and 
HUVECs were used at comparable passage numbers. The same kits and reagents were used 
for the experiments wherever possible. Data presented are mean ± S.E.M. where n denotes 
the number of experiments in triplicates. A P-value of <0.05 was considered statistically 
significant.  Data were analysed with GraphPad Prism 6.0 (GraphPad Software Inc., San 
Diego, CA, USA) to produce dose-response curves using XY analyses with non-linear 
regression in a bell-shape fit. The EC50 and IC50 values were obtained using XY analyses 
with non-linear regression and the log (agonist or inhibitor) vs. response function. Statistical 
tests preformed were a Student’s t-test or a one-way analysis of variance (ANOVA) tests 
accompanied by Bonferroni post hoc test. 
 
 
3.  Results 
3.1  Ala
1
-angiotensin-(1-7) stimulates the generation of intracellular cAMP in endothelial 
cells 
As we previously demonstrated that Ang-(1-7) can increase intracellular cAMP in a dose-
dependent manner (Tetzner et al., 2016), we first tested whether Ala1-Ang-(1-7) can act in a 
similar manner using the most commonly characterized endothelial cell-line, human 
umbilical vein endothelial cells (HUVEC). Although Ala1-Ang-(1-7) was comparably as 
efficient as Ang-(1-7), the dose-response curve showed a completely different appearance 
(Fig. 1A). Not only is the curve bell-shaped in contrast to the one generated by Ang-(1-7) 
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which runs into a plateau with increasing concentrations, the increase in cAMP occurs much 
earlier with a leftward shift of almost 3 magnitudes of order (EC50 was reached at 3.6 x 10
-
11M with Ala1-Ang-(1-7) and at 1.1 x 10-8M with Ang-(1-7)).  
To investigate whether this effect on cAMP is mediated by receptors that are sensitive to the 
two Ang-(1-7) antagonists, A779 and D-Pro, and to the unspecific AT2 receptor blocker 
PD123319, which we identified as also blocking the Ang-(1-7) receptors Mas and MrgD 
(Tetzner et al., 2016), we used Ala1-Ang-(1-7) in the concentration of highest efficacy (10-
9M) without and with the 3 receptor blockers (10-6M). As shown in Fig. 1B, the three 
compounds did not affect base-line cAMP concentrations, but all three blockers significantly 




-angiotensin-(1-7) stimulates the generation of intracellular cAMP in HEK293 
cells expressing MrgD  
Based on our work with Ang-(1-7) (Tetzner et al., 2016) and the results published by 
Lautner et al.,(Lautner et al., 2013), we then tested Mas- and MrgD-transfected cells. As 
shown in Fig. 2A, Ala1-Ang-(1-7) stimulation caused a dose-dependent increase in the 
intracellular cAMP level in MrgD-transfected cells with an EC50 of 3.98 x 10
-13M. Since in 
HUVEC the dose-response curve peaked at 10-9M of Ala1-Ang-(1-7) but in MrgD-transfected 
cells at 10-11M, we selected 10-11M for further tests with the previously effective blockers. 
Fig. 2B shows that none of the 3 blockers had a baseline effect on cAMP levels in the 
pcDNA3.1 control or in MrgD-transfected cells. However, the increase in cAMP 
concentration generated by Ala1-Ang-(1-7) in MrgD-transfected cells was blocked by D-Pro 








-angiotensin-(1-7) stimulates the generation of intracellular cAMP in HEK293 
cells expressing Mas 
In experiments with HEK293 cells transfected with the Mas receptor, Ala1-Ang-(1-7) also 
caused a dose-dependent increase in cAMP concentration with an EC50 value of 1.58 x 10
-
12M reaching highest efficacy at 5 x 10-11M (Fig. 2C). In contrast to MrgD-transfected cells, 
D-Pro, PD123319 and A779 all blocked the Ala1-Ang-(1-7)-mediated increase in cAMP level 




-angiotensin-(1-7) in higher concentrations activates Gαi, reducing the generation 
of cAMP 
As cAMP is generated by the enzyme adenylyl cyclase which can be activated by Gαs but also 
inhibited by Gαi signalling, we hypothesised that the bell-shaped curve could be the result of a 
Gαi activation when using higher concentrations of Ala
1-Ang-(1-7). We used MrgD receptor-
transfected cells and generated dose-response curves for Ala1-Ang-(1-7) with and without 
pre-treatment with PTX, a Gαi inhibitor, which prevents the Gαi proteins from interacting with 
the receptor. Since the Gαi subunits remain locked in their inactive state, they are unable to 
inhibit adenylate cyclase activity. As shown in Fig. 3A, the parallel treatment with PTX 




We then carried out identical experiments with PTX using Mas-transfected cells. As 
shown in Fig. 3B, the parallel treatment with PTX also prevented the decline in 
intracellular cAMP level with higher concentration of Ala1-Ang-(1-7), as seen for MrgD-
transfected cells before (Fig. 3A). 
To confirm the PTX data, we used a second, selective Gαi inhibitor, NF 023 (Freissmuth 
et al., 1996). As for PTX, treatment with NF 023 prevented the decline in intracellular 
cAMP concentrations with increasing concentrations of Ala1-Ang-(1-7) in both Mas and 
MrgD-transfected cells (Fig. 3C). 
To confirm specific overexpression of mRNA for both receptors, we measured expression of 
receptor mRNA in MrgD and Mas-transfected cells to illustrate transfection efficacy. As 
shown in Fig. 3D, transfection with Mas or MrgD plasmids led to a significant 
overexpression of the receptor mRNA. 
To visualise the transfection efficacy on protein level, HEK293 cells were transfected 
with Mas-mCherry or MrgD-GFP as seen in Fig. 3E. In transfected cells carrying the 
receptor cDNA, both receptors are expressed in the cytoplasmic membranes of these 
cells. 
 
3.5  Absence of Ala
1
-angiotensin-(1-7)-mediated cAMP generation in mesangial cells 
derived from Mas/MrgD knockout animals 
To test whether the lack of Mas and MrgD blunts the ability of Ala1-Ang-(1-7) to generate 
cAMP in primary mesangial cells, as previously examined in Ang-(1-7), we used mesangial 
cells derived from double knockout mice deficient in both receptors, a strain introduced 
recently (Tetzner et al., 2016). Ala1-Ang-(1-7) increased cAMP dose-dependently in wild-
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type mesangial cells (EC50 = 5.37 X 10
-13M) with a typical bell-shape curve as shown before 
in endothelial cells, and Mas or MrgD-transfected HEK cells. (Fig. 4A). While D-Pro, 
PD123319 and A779 did not affect base-line cAMP concentrations in mesangial cells, all 
three compounds blocked the Ala1-Ang-(1-7)-mediated increase in cAMP level in these wild-
type cells (Fig. 4B). This cAMP increase observed in wild-type mesangial cells was 
completely blunted in mesangial cells isolated from double-knockout mice (Fig. 4C). In 
addition, Forskolin, a direct adenylyl cyclase activator, increased cAMP concentration in 
DKO mesangial cells, illustrating that the lack of stimulation by Ala1-Ang-(1-7) is not based 
on a general inefficacy of the cells to generate cAMP in response to stimulation. 
Next, we tested whether the Ala1-Ang-(1-7)-mediated increase in cAMP observed in WT 
mesangial cells could be abolished in Mas or MrgD KO cells or whether it required 
deficiency in both receptors. Knockout in one of the receptors did not significantly 
reduce the Ala1-Ang-(1-7) signal generated in wild-type cells, while the double knockout 
again completely blunted the effect (Fig. 4D). 
 
3.6  In silico modelling to explain the differences in potency between Ala1-angiotensin-(1-
7)-and angiotensin-(1-7) 
The proposed binding mode of Ang-(1-7) places Arg2 in a position to establish a salt 
bridge with Glu167 and a cation-π interaction with Tyr248 of the Mas receptor. These 
interactions constrain the mobility of the N-terminal part of Ang-(1-7) and prevent the 
negatively charged carboxylate in Asp1 side chain from interacting with a positive 
chemical group in the protein (see Fig. 5A, where Arg181 and Arg185 of Mas receptor are 
explicitly shown, as they are the closest positively charged residues to Ang-(1-7)). 
Actually, the electrostatic potential surface of the binding site is estimated with a 
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positive surface area value of 5 Å2 and a much greater negative surface area value of 
109 Å2 (considering residues within 5 Å of Ang-(1-7)). This predominance of a 
negatively charged protein surface is more stressed on the extracellular side (where the 
N-terminal Ang-(1-7) is predicted to bind), as seen in Fig. 5A. Fig. 5B shows the 
complementarity between the electrostatic potential surfaces of both Ang-(1-7) and the 
receptor. There is a close contact of non-complementary areas around the side chains of 
Asp1 of Ang-(1-7) and Asp173 of the receptor. This is mainly due to the proximity of 
negatively charged areas. The fact that Ala1-Ang-(1-7) does not have a negatively 
charged carboxylate group in the first residue may stabilise its interactions with the 
receptor and, thus, could be a reason for its greater potency in comparison to Ang-(1-7). 
 
4.  Discussion 
Here, we demonstrate that Ala1-Ang-(1-7), like Ang-(1-7), stimulates the generation of the 
second messenger, cAMP, and cAMP is thus an ideal tool to quantify changes in intracellular 
signalling mediated by Ala1-Ang-(1-7). Using this readout allowed us to provide final 
pharmacological evidence that MrgD is a functional receptor for Ala1-Ang-(1-7). More 
importantly, the use of cAMP as a readout enabled us to generate results providing the first 
experimental proof that Mas is the second receptor for Ala1-Ang-(1-7). Furthermore, our data 
confirm findings with Ang-(1-7) (Tetzner et al., 2016), that A779 fails to significantly reduce 
the stimulation of cAMP production by Ala1-Ang-(1-7) in MrgD-transfected cells. This may 
be due to the D-orientation of alanine in position 7, which might prevent the peptide fitting 




Previous work by other groups implicated that the two Ang peptides, Ang-(1-7) and Ala1-
Ang-(1-7) target different receptors, with Ala1-Ang-(1-7) stimulating MrgD but not Mas 
(Lautner et al., 2013). Our data shows that not only can Ang-(1-7) can signal via Mas and 
MrgD, but also the decarboxylated version of the heptapeptide, Ala1-Ang-(1-7). One of the 
reasons for this discrepancy might be due to our finding that Ala1-Ang-(1-7) generates a bell-
shaped dose response curve and is much more potent than Ang-(1-7). Consequently, at 
concentrations where Ang-(1-7) is most efficient, Ala1-Ang-(1-7) might have little effect as it 
is back to base-line levels of cAMP. However, since we measured cAMP, while others 
looked on NO release, it would be interesting to see whether increasing concentrations of 
Ala1-Ang-(1-7) would also generate a dose-response curve for NO, with highest efficiency 
similar to the EC50 described here for receptor-transfected cells and primary kidney and 
endothelial cells. Nevertheless, our findings are also supported by modelling of Ang-(1-7) in 
the Mas receptor binding site, in which the decarboxylation of the first residue could lead to a 
more favorable electrostatic complementary with the receptor surface and thus, making it 
likely that the Mas receptor could also be a receptor for Ala1-Ang-(1-7).  
While our data excludes a receptor fingerprint discriminating between both peptides, one of 
the key findings of our experiments is that Ala1-Ang-(1-7) is much more potent than Ang-(1-
7), although the difference between both peptides seems marginal, with only a lack of the 
carboxylate group in Ala1-Ang-(1-7).  
To better understand the reason for improved potency, we investigated the potential binding 
mode of the N-terminal segment of Ang-(1-7), as well as the electrostatic potential of the 
binding site and its complementarity to Ang-(1-7). Our predictions show how the Asp1 side 
chain may not be stabilised due to a charge repulsion with the highly negatively charged 
surface of the receptor, although the water accessibility of this area could screen this effect 
(screening is the damping of electric fields). The fact that Ala1-Ang-(1-7) does not have the 
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carboxylate group in the first residue, thus avoiding a potential charge repulsion with the 
predominantly negatively charged area, may be a reason for its observed increased potency. 
In addition, this same absence may favour a salt bridge between the N-terminal amino group 
and the Mas receptor, particularly with Asp173. Thus, the interactions extracted from this 
model might build the base for a screening program to identify agonists stimulating Mas and 
MrgD. 
Another very dominant pharmacodynamic difference between the two peptides is the bell-
shaped dose-response curve for Ala1-Ang-(1-7). There are hints in the literature, which might 
explain this bell-shaped dose-response curve. Since the late nineties, different groups have 
shown the ß2-adrenergic receptor to couple not only to Gαs, but also to Gαi proteins in the 
heart (Xiao et al., 1995, Xiao et al., 1999) and in receptor-transfected HEK293 cells (Daaka 
et al., 1997), whereby the degree of activation of the two G proteins would define the agonist 
effect on intracellular cAMP concentrations. Interestingly, it has been also shown that this 
dual activation is not specific for the ß2-adrenergic receptor but has also been seen in 
histamine, serotonin, and glucagon receptors (Kilts et al., 2000). 
A decade ago, Beyermann et al. (Beyermann et al., 2007) confirmed this model by using the 
corticotropin-releasing factor receptor type 1. They demonstrated that native ligands 
stimulated Gαi and Gαs proteins, whereby in all cases, Gαi.has been activated approx. two 
magnitudes of order to the right. Therefore, we tested whether Ala1-Ang-(1-7) could also lead 
to an Gαi activation in higher concentrations, reducing the Gαs-mediated increase in cAMP. 
By using PTX, a substance that prevents Gαi-associated inhibition of adenylyl synthase 
leading to a reduction in intracellular cAMP, the decline in the dose response curve observed 
with Ala1-Ang-(1-7) alone, disappeared. The curve runs in a plateau following PTX treatment 
and looked similar to the Ang-(1-7) curve, although with a significant leftward shift. Thus, it 
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looks like Ala1-Ang-(1-7), but not Ang-(1-7) can activate two G proteins, and thus, similar to 
a car, by pressing the gas and brake pedal, it brings the speed (an increase in cAMP) to zero. 
The authors are aware that limitations of our study include the lack of knowledge in whether 
the decarboxylation of Ang-(1-7) to Ala1-Ang-(1-7) results in any loss or gain of funcion in 
vivo, which can only be evaluated by animal and human studies. However, the enzyme being 
responsible for the reaction is still unidentified and thus, its inhibition / knockout in vivo can 
still not be experimentally realized. 
Taken together, our results change the view on Ala1-Ang-(1-7) as a peptide exclusively 
activating MrgD but not Mas, illustrate that minor changes in Ang-(1-7) (decarboxylation on 
amino acid 1) can lead to major changes in the response of both receptors and provide a 
mechanistic explanation for such differences. Thus, by considering the structural 
differences in Ala1-Ang-(1-7) and the resulting improvement in potency, our data lays the 
foundation for the development of new Ang-(1-7) analogues which may generate a more 
potent stimulation of the receptors and hence, leading to safer and more efficient treatment 
options for a growing number of diseases in which Ang-(1-7) might be beneficial, based on 
its success in preclinical disease models.  
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Fig. 1: Intracellular cAMP is increased by Ala1-Angiotensin-(1-7) in human umbilical 
vein endothelial cells (HUVEC). (A) HUVEC were stimulated for 15min with a range of 
concentrations (10-6 to 10-13M) of Ala1-Ang-(1-7) before analysis of cAMP concentration. (B) 
HUVEC were stimulated for 15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and 
PD123319 (all 10-6 M)), followed by 15min stimulation with Ala1-Ang-(1-7) (10-9 M). 
Results are expressed as mean ± S.E.M.; (A) n=3, (B) n=4. Data was reported as a fold 
change or percentage of the untreated control mean. ***P<0.001, significantly different from 
control; ###P<0.001, ##P<0.01 or #P<0.05, significantly different from Ala1-Ang-(1-7); 
ANOVA with Bonferoni post-hoc test. 
 
Fig. 2: Ala1-Ang-(1-7) signals through MrgD and Mas receptors. (A) MrgD-transfected 
HEK293 cells were stimulated for 15min with a range of concentrations (10-6 to 10-18M) of 
Ala1-Ang-(1-7) before analysis of cAMP concentration. (B) Cells were stimulated for 15min 
with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 10-6M)), followed by 
15min stimulation with Ala1-Ang-(1-7) (10-11M). (C) Mas-transfected HEK293 cells were 
stimulated for 15min with a range of concentrations (10-6 to 10-18M) of Ala1-Ang-(1-7) before 
analysis of cAMP concentration. (D) Cells were stimulated for 15min with blockers (all 10-
6M)), followed by 15min stimulation with Ala1-Ang-(1-7) (10-11M). Results are expressed as 
mean ± S.E.M.; (A) n=4, (B) n=5, (C) n=6 and (D) n=5. Data was reported as a fold change 
or percentage of the untreated control mean.  ***P<0.001, significantly different from the 
MrgD control; ###P<0.001, significantly different from Ala1-Ang-(1-7); ANOVA with 
Bonferoni post-hoc test. 
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Fig. 3: Ala1-Ang-(1-7) in higher concentrations activates Gαi. (A) MrgD-transfected 
HEK293 cells were stimulated for 15min with PTX (50ng/ml) followed by stimulation with 
Ala1-Ang-(1-7) (10-11M) for a further 15min. (B) Mas-transfected HEK293 cells were 
stimulated with PTX, followed by stimulation with 3 doses of Ala1-Ang-(1-7) (10-7, 10-11 
& 10-14M) for a further 15min. (C) HEK293 cells were stimulated for 15min with NF 
023 (5x10-6M) followed by stimulation with 3 doses of Ala1-Ang-(1-7) (10-7, 10-11 & 10-
14M) for a further 15min. (D) mRNA of Mas and MrgD-transfected HEK293 cells 
(pcDNA3.1 values are set as 1). (E) Fluorescence microscopy of HEK293 cells transfected 
with Mas-mCherry (red) and MrgD-GFP (green). Results are expressed as mean ± 
S.E.M.; (A) n=4, (B) n=2, (C) n=3 and (D) n=6. Data was reported as a fold change or 
percentage of the untreated control. ***P<0.001, **P<0.01, significantly different from 
pcDNA3.1 control; ###P<0.001, significantly different from Ala1-Ang-(1-7) 10-7M; 
$$
P<0.01, $$$P<0.001, significantly different from Ala1-Ang-(1-7) 10-14M; ANOVA with 
Bonferoni post-hoc test and Students T-test. 
 
Fig. 4: Ala1-Ang-(1-7) induced signalling is absent in mesangial cells derived from 
Mas/MrgD double-knockout animals. (A) WT C57BL/6 mesangial cells were stimulated 
for 15min with a range of concentrations (10-6 to 10-14M) of Ala1-Ang-(1-7) before analysis 
of cAMP concentration. (B) WT C57BL/6 mesangial cells were stimulated for 15min with 
blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 (all 10-6M)), followed by 15min 
stimulation with Ala1-Ang-(1-7) (10-11M). (C) Mas/MrgD knockout (DKO) mesangial cells 
were stimulated for 15min with blockers (A779, D-Pro7-Ang-(1-7) (D-Pro) and PD123319 
(all 10-6M)), followed by 15min stimulation with Ala1-Ang-(1-7) (10-11M). (D) WT, Mas 
KO, MrgD KO and DKO mesangial cells were stimulated for 15min with Ala1-Ang-(1-
7) (10-11M). Results are expressed as mean ± S.E.M.; (A) n=6, (B) n=5, (C) n=2 and (D) n= 
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2-5. Untreated control values of each genotype is set as 100%. ***P<0.001, *P<0.05, 
significantly different from control mean; 
###
P<0.001, #P<0.05, significantly different from 
Ala1-Ang-(1-7); ANOVA with Bonferoni post-hoc test. 
 
Fig. 5: Electrostatic potential in Mas receptor binding site model. (A) Electrostatic 
potential of Mas receptor model, considering residues within 10 Å of the predicted binding 
pose of Ang-(1-7). (B) Electrostatic potential of Ang-(1-7) peptide in its predicted binding 
pose (solid surface) and Mas receptor model (mesh surface), considering residues within 3 Å 
of Ang-(1-7). Red areas are favourable to interact with positively charged groups and blue 
ones with negatively charged groups. Predicted binding pose of Ang-(1-7) is depicted in 
green-coloured carbon atoms. Ang-(1-7) residue labels are shown in italic type. 
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